Figure 1.
![ORR and BOR by azole subgroup in patients with GVHD. Patients with SR-aGVHD (A) and patients with SR-cGVHD (B) treated with ruxolitinib (RUX) or BAT, with or without azoles. Panel A shows ORR (CR + PR) and BOR at day 28 (aGVHD [full analysis set]). Panel B shows ORR (CR + PR) and BOR at week 24 (cGVHD [full analysis set]). OR, odds ratio.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/16/10.1182_bloodadvances.2025016212/2/blooda_adv-2025-016212-gr1.jpeg?Expires=1760688461&Signature=Jya5xh3GuW2DfwjC6XOJ5F2W~qQBJdLZF5NadHCc3w5DlPADqMpKfOO0gBoQcxlY2N-8LcC~9lZZ7FZEcZ0NYT05J~~LHYt2wrZeyR15ZsOYKVt0oBf7~1L67NFZk~BOeQBQaLZDG7Boc4LVtJeZnMp15Efn~M-HpUNzEARCVOmnpdo8tIKXOeHqxcYgZ1lPpqR8~XW7D8MQq3Paz2eoupL0IsDLMzCCCANNMbzMsexpXZ9s27g6mK3Pzy1DITe98Ro5B7ZpVWLxeVfoq5I5v4PZWWJC35o2SSZExI9x3kqWsOsi7mezIPNHSCiFKw~zqn1zdKtuOtjja6bujzwR9A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
ORR and BOR by azole subgroup in patients with GVHD. Patients with SR-aGVHD (A) and patients with SR-cGVHD (B) treated with ruxolitinib (RUX) or BAT, with or without azoles. Panel A shows ORR (CR + PR) and BOR at day 28 (aGVHD [full analysis set]). Panel B shows ORR (CR + PR) and BOR at week 24 (cGVHD [full analysis set]). OR, odds ratio.
